Want to see FR:SAN full AI Analyst Report?
SAN Stock Chart & Stats
€78.74
€1.76(2.31%)
At close: 4:00 PM EDT
€78.74
€1.76(2.31%)
Day’s Range― - ―
52-Week Range€69.75 - €91.15
Previous CloseN/A
Volume1.79M
Average Volume (3M)2.27M
Market Cap
€88.25B
Enterprise Value€108.09B
Total Cash (Recent Filing)€6.35B
Total Debt (Recent Filing)€23.58B
Price to Earnings (P/E)22.5
Beta0.83
Next Earnings
Oct 30, 2026EPS Estimate
2.79Next Dividend Ex-DateN/A
Dividend Yield11.33%
Share Statistics
EPS (TTM)3.27
Shares Outstanding1,207,773,400
10 Day Avg. Volume2,188,885
30 Day Avg. Volume2,266,085
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.16
P/FCF Ratio11.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€91.27Price Target Upside15.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)8.58
Revenue Forecast (FY)€49.73B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSanofi’s substantial operating and free cash flow provides funding for research, launches, dividends and business development without relying heavily on external financing. High free-cash-flow conversion also indicates that reported earnings are supported by cash, strengthening resilience through changing product cycles.
Dupixent Commercial StrengthDupixent’s broad patient reach, volume-led growth and expansion across indications create a substantial commercial foundation for Sanofi. The product’s scale can support investment in new medicines while its established position strengthens the company’s specialty-care franchise over the next several quarters.
Growing Launch PortfolioRapid growth from multiple launches reduces reliance on a single newly introduced product and shows that Sanofi is converting its development portfolio into commercial revenue. Broad momentum across disease areas can improve product mix and provide durable growth as newer medicines mature.
Bears Say
Compressed ProfitabilityThe sharp reduction in net profit margin means less revenue is being converted into earnings than in recent years, while modest ROE signals weaker capital efficiency. If this persists, it could limit internal funding capacity and reduce the benefit of otherwise healthy sales and gross-margin performance.
Pipeline Execution SetbacksMultiple late-stage failures and discontinuations weaken confidence in near- and medium-term pipeline productivity. They can increase the need for external business development, delay replacement growth for mature products, and make future earnings more dependent on successful execution from the remaining programs.
Manufacturing And Supply DisruptionSupply interruptions affecting established Pompe medicines can reduce near-term revenue and disrupt treatment continuity for patients. The cited quality and production issues also require remediation and stabilization, creating an operational burden that may continue affecting commercial reliability over the next several months.
Sanofi News
SAN FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was €69.75 and its highest was €91.15 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is €88.25B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Oct 30, 2026 which is in 7 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jul 30, 2026. The company reported €2.09 earnings per share for the quarter, beating the consensus estimate of €1.899 by €0.191.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Semiannually dividend of €4.12 which represents an annual dividend yield of 11.33%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 2.79.
How many shares outstanding does Sanofi have?
Sanofi has 1,207,773,400 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €2.09 in its last earnings report, beating expectations of €1.899. Following the earnings report the stock price went down -8.946%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in FR:SAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi
Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
SAN Company Deck
SAN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive, supported by strong Q2 sales, EPS growth, broad launch momentum, continued Dupixent demand, raised 2026 guidance and higher Dupixent and combined 2030 ambitions. However, management also acknowledged meaningful challenges, including expected second-half moderation, vaccine declines and a lower vaccine ambition, R&D productivity issues, multiple pipeline setbacks, China momentum challenges and investor credibility concerns. The strength of the reported results and commercial outlook outweighed the stated risks and setbacks.View all FR:SAN earnings summariesSAN Stock 12 Month Forecast
Average Price Target
€91.27
▲(15.91% Upside)